Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Abstract B042: Dissection of the T cell infiltrate in mouse pancreatic tumors reveals a diverse tumor-reactive T cell repertoire targeting neoantigens and tumor-associated antigens

Stefan Zens, Hannes Kehm, Daniel Baumann, Aline Konrad, Zibo Meng, Arnoud H. de Ru, Julian Mochayedi, Francesca Lucato, Angelika B. Riemer, Isabel Poschke, Michael Volkmar, Peter A. van Veelen, Rienk Offringa

Cancer Res (2024) 84 (17_Supplement_2): B042.

https://doi.org/10.1158/1538-7445.PANCREATIC24-B042

Published: 15 September 2024

View article titled, Abstract B042: Dissection of the T cell infiltrate in mouse pancreatic tumors reveals a diverse tumor-reactive T cell repertoire targeting neoantigens and tumor-associated antigens

Journal Articles

Abstract IA-02: The tumor-reactive CD8+ T-cell repertoire in pancreatic cancer as revealed by single-cell sequencing

Rienk Offringa

Cancer Res (2024) 84 (17_Supplement_2): IA-02.

https://doi.org/10.1158/1538-7445.PANCREATIC24-IA-02

Published: 15 September 2024

View article titled, Abstract IA-02: The tumor-reactive CD8+ T-cell repertoire in pancreatic cancer as revealed by single-cell sequencing

Journal Articles

Abstract B079: Identification of synergistic drug combinations including MEK inhibitor and agents modulating the tumor microenvironment in an electroporation-induced pancreatic cancer model

Aline S. Konrad, Tanja Hägele, Stefan Zens, Caroline Vent, Moritz Hamberger, Sarah Baiker, Aron Maes, Carl-Stephan Leonhardt, Oliver Strobel, Oliver Politz, Dieter Zopf, Daniel Baumann, Julian Mochayedi, Rienk Offringa

Cancer Res (2024) 84 (2_Supplement): B079.

https://doi.org/10.1158/1538-7445.PANCA2023-B079

Published: 16 January 2024

View article titled, Abstract B079: Identification of synergistic drug combinations including MEK inhibitor and agents modulating the tumor microenvironment in an electroporation-induced pancreatic cancer model

Journal Articles

Abstract ND04: BAY 2965501: A highly selective DGK- ζ inhibitor for cancer immuno-therapy with first-in-class potential

Rienk Offringa, Catherine Olesch, Frederik Cichon, Mareike Grees, Norbert Schmees, Ulrike Roehn, Florian Prinz, Judith Guenther, Detlef Stoeckigt, Michael Erkelenz, Thi Thanh Uyen Nguyen, Ulf Boemer, Nicolas Werbeck, Marc Kunze, Kirstin Petersen, Dennis Kirchhoff

Cancer Res (2023) 83 (7_Supplement): ND04.

https://doi.org/10.1158/1538-7445.AM2023-ND04

Published: 29 May 2023

View article titled, Abstract ND04: BAY 2965501: A highly selective DGK- ζ inhibitor for cancer immuno-therapy with first-in-class potential

Journal Articles

Abstract 3650: Trace'n'Seq: Assessing neuronal infiltration and its impact in pancreatic ductal carcinoma

Vera Thiel, Simon Renders, Jasper Panten, Julian Mochayedi, Rienk Offringa, Martin Sprick, Andreas Trumpp

Cancer Res (2022) 82 (12_Supplement): 3650.

https://doi.org/10.1158/1538-7445.AM2022-3650

Published: 15 June 2022

View article titled, Abstract 3650: Trace'n'Seq: Assessing neuronal infiltration and its impact in pancreatic ductal carcinoma

Journal Articles

Abstract 1722: Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1

Cancer Res (2021) 81 (13_Supplement): 1722.

https://doi.org/10.1158/1538-7445.AM2021-1722

Published: 01 July 2021

View article titled, Abstract 1722: Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1

Journal Articles

Abstract LB-075: Increased T cell- activation resulting from the combination of the anti-CEACAM6 function-blocking antibody BAY 1834942 with checkpoint inhibitors targeting either PD-1/PD-L1 or TIM-3

Joerg Willuda, Hans-Henning Boehm, Jessica Pinkert, Mark Trautwein, Wolf-Dietrich Doecke, Oliver von Ahsen, Karl Ziegelbauer, Rienk Offringa, Bertolt Kreft, Philipp Beckhove

Cancer Res (2019) 79 (13_Supplement): LB-075.

https://doi.org/10.1158/1538-7445.AM2019-LB-075

Published: 01 July 2019

View article titled, Abstract LB-075: Increased T cell- activation resulting from the combination of the anti-CEACAM6 function-blocking antibody BAY 1834942 with checkpoint inhibitors targeting either PD-1/PD-L1 or TIM-3

Journal Articles

Abstract 1771: BAY 1834942 is an immunotherapeutic antibody blocking the novel immune checkpoint regulator CEACAM6 (CD66c)

Cancer Res (2018) 78 (13_Supplement): 1771.

https://doi.org/10.1158/1538-7445.AM2018-1771

Published: 01 July 2018

View article titled, Abstract 1771: BAY 1834942 is an immunotherapeutic antibody blocking the novel immune checkpoint regulator CEACAM6 (CD66c)

Journal Articles

Abstract 2339: RNAi discovery platform to identify novel genes that prevent immune surveillance in pancreatic ductal adenocarcinoma (PDAC)

Antonio Sorrentino, Ayse Nur Menevse, Tillmann Michels, Nisit Khandelwal, Marco Breinig, Isabel Poschke, Valentina Volpin, Sabrina Wagner, Rienk Offringa, Michael Boutros, Philipp Beckhove

Cancer Res (2016) 76 (14_Supplement): 2339.

https://doi.org/10.1158/1538-7445.AM2016-2339

Published: 15 July 2016

View article titled, Abstract 2339: RNAi discovery platform to identify novel genes that prevent immune surveillance in pancreatic ductal adenocarcinoma (PDAC)

Journal Articles

Abstract 245: Identification of novel immune checkpoints as potential therapeutic targets in pancreatic ductal adenocarcinoma (PDAC) using RNAi screening

Antonio Sorrentino, Tillmann Michels, Ayse Nur Menevse, Nisit Khandelwal, Marco Breinig, Isabel Poschke, Rienk Offringa, Michael Boutros, Philipp Beckhove

Cancer Res (2015) 75 (15_Supplement): 245.

https://doi.org/10.1158/1538-7445.AM2015-245

Published: 01 August 2015

View article titled, Abstract 245: Identification of novel immune checkpoints as potential therapeutic targets in pancreatic ductal adenocarcinoma (PDAC) using RNAi screening

Journal Articles

Abstract 254: TiMi1 is a novel immune-checkpoint in solid tumors identified via a tumor-infiltrating lymphocyte (TIL)-based RNAi screening

Tillmann Michels, Christina A. Hartl, Nisit Khandelwal, Marco Breinig, Antonio Sorrentino, Christina Mäder, Ludmila Umansky, Isabel Poschke, Rienk Offringa, Michael Boutros, Galit Eisenberg, Michal Lotem, Philipp Beckhove

Cancer Res (2015) 75 (15_Supplement): 254.

https://doi.org/10.1158/1538-7445.AM2015-254

Published: 01 August 2015

View article titled, Abstract 254: TiMi1 is a novel immune-checkpoint in solid tumors identified via a tumor-infiltrating lymphocyte (TIL)-based RNAi screening

Journal Articles

Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2D^b in Complex with the Melanoma-Associated Epitope gp100

Marianne J.B. van Stipdonk, Daniel Badia-Martinez, Marjolein Sluijter, Rienk Offringa, Thorbald van Hall, Adnane Achour

Cancer Res (2009) 69 (19): 7784–7792.

https://doi.org/10.1158/0008-5472.CAN-09-1724

Published: 01 October 2009

View article titled, Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

Includes: Supplementary data

Journal Articles

Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell–Mediated Targeting of Carcinoembryonic Antigen

Rinke Bos, Suzanne van Duikeren, Hans Morreau, Kees Franken, Ton N.M. Schumacher, John B. Haanen, Sjoerd H. van der Burg, Cornelis J.M. Melief, Rienk Offringa

Cancer Res (2008) 68 (20): 8446–8455.

https://doi.org/10.1158/0008-5472.CAN-08-1864

Published: 15 October 2008

View article titled, Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell–Mediated Targeting of Carcinoembryonic Antigen

Journal Articles

Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen

Marjolein M. Lauwen, Sander Zwaveling, Linda de Quartel, S. Carmela Ferreira Mota, Janine A.C. Grashorn, Cornelis J.M. Melief, Sjoerd H. van der Burg, Rienk Offringa

Cancer Res (2008) 68 (3): 893–900.

https://doi.org/10.1158/0008-5472.CAN-07-3166

Published: 01 February 2008

View article titled, Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen

Journal Articles

Induction of Protective CTL Immunity against Peptide Transporter TAP-Deficient Tumors through Dendritic Cell Vaccination

Benedict Chambers, Per Grufman, Vanoohi Fredriksson, Kenth Andersson, Marjet Roseboom, Sandra Laban, Marcel Camps, Elisabeth Z. Wolpert, Emmanuel J.H.J. Wiertz, Rienk Offringa, Hans-Gustaf Ljunggren, Thorbald van Hall

Cancer Res (2007) 67 (18): 8450–8455.

https://doi.org/10.1158/0008-5472.CAN-07-1092

Published: 17 September 2007

View article titled, Induction of Protective CTL Immunity against Peptide Transporter TAP-Deficient Tumors through Dendritic Cell Vaccination

Journal Articles

High Number of Intraepithelial CD8⁺ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

Sytse J. Piersma, Ekaterina S. Jordanova, Mariëtte I.E. van Poelgeest, Kitty M.C. Kwappenberg, Jeanette M. van der Hulst, Jan W. Drijfhout, Cornelis J.M. Melief, Gemma G. Kenter, Gert Jan Fleuren, Rienk Offringa, Sjoerd H. van der Burg

Cancer Res (2007) 67 (1): 354–361.

https://doi.org/10.1158/0008-5472.CAN-06-3388

Published: 08 January 2007

View article titled, High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

Journal Articles

CD4⁺ T Cells Are Able to Promote Tumor Growth through Inhibition of Tumor-Specific CD8⁺ T-Cell Responses in Tumor-Bearing Hosts

Annemieke Th. den Boer, Geertje J.D. van Mierlo, Marieke F. Fransen, Cornelis J.M. Melief, Rienk Offringa, René E.M. Toes

Cancer Res (2005) 65 (15): 6984–6989.

https://doi.org/10.1158/0008-5472.CAN-04-3344

Published: 01 August 2005

View article titled, CD4+ T Cells Are Able to Promote Tumor Growth through Inhibition of Tumor-Specific CD8+ T-Cell Responses in Tumor-Bearing Hosts

Journal Articles

Expression of a Natural Tumor Antigen by Thymic Epithelial Cells Impairs the Tumor-Protective CD4+ T-Cell Repertoire

Rinke Bos, Suzanne van Duikeren, Thorbald van Hall, Patricia Kaaijk, Richard Taubert, Bruno Kyewski, Ludger Klein, Cornelis J.M. Melief, Rienk Offringa

Cancer Res (2005) 65 (14): 6443–6449.

https://doi.org/10.1158/0008-5472.CAN-05-0666

Published: 15 July 2005

View article titled, Expression of a Natural Tumor Antigen by Thymic Epithelial Cells Impairs the Tumor-Protective CD4+ T-Cell Repertoire

Journal Articles

Stable suppression of mutant KRAS in C26 murine colon carcinoma cells by RNA interference leads to complete loss of metastatic potential and to increased tumor immunity.

Niels Smakman, Inne Borel Rinkes, Rinke Bos, Rienk Offringa, Onno Kranenburg

Cancer Res (2005) 65 (9_Supplement): 78.

Published: 01 May 2005

View article titled, Stable suppression of mutant KRAS in C26 murine colon carcinoma cells by RNA interference leads to complete loss of metastatic potential and to increased tumor immunity.

Journal Articles

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

Annemieke de Jong, Mariëtte I. E. van Poelgeest, Jeanette M. van der Hulst, Jan Wouter Drijfhout, Gert Jan Fleuren, Cornelis J. M. Melief, Gemma Kenter, Rienk Offringa, Sjoerd H. van der Burg

Cancer Res (2004) 64 (15): 5449–5455.

https://doi.org/10.1158/0008-5472.CAN-04-0831

Published: 02 August 2004

View article titled, Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

NARROW

Abstract B042: Dissection of the T cell infiltrate in mouse pancreatic tumors reveals a diverse tumor-reactive T cell repertoire targeting neoantigens and tumor-associated antigens

Abstract IA-02: The tumor-reactive CD8+ T-cell repertoire in pancreatic cancer as revealed by single-cell sequencing

Abstract B079: Identification of synergistic drug combinations including MEK inhibitor and agents modulating the tumor microenvironment in an electroporation-induced pancreatic cancer model

Abstract ND04: BAY 2965501: A highly selective DGK- ζ inhibitor for cancer immuno-therapy with first-in-class potential

Abstract 3650: Trace'n'Seq: Assessing neuronal infiltration and its impact in pancreatic ductal carcinoma

Abstract 1722: Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1

Abstract LB-075: Increased T cell- activation resulting from the combination of the anti-CEACAM6 function-blocking antibody BAY 1834942 with checkpoint inhibitors targeting either PD-1/PD-L1 or TIM-3

Abstract 1771: BAY 1834942 is an immunotherapeutic antibody blocking the novel immune checkpoint regulator CEACAM6 (CD66c)

Abstract 2339: RNAi discovery platform to identify novel genes that prevent immune surveillance in pancreatic ductal adenocarcinoma (PDAC)

Abstract 245: Identification of novel immune checkpoints as potential therapeutic targets in pancreatic ductal adenocarcinoma (PDAC) using RNAi screening

Abstract 254: TiMi1 is a novel immune-checkpoint in solid tumors identified via a tumor-infiltrating lymphocyte (TIL)-based RNAi screening

Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2D^b in Complex with the Melanoma-Associated Epitope gp100

Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell–Mediated Targeting of Carcinoembryonic Antigen

Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen

Induction of Protective CTL Immunity against Peptide Transporter TAP-Deficient Tumors through Dendritic Cell Vaccination

High Number of Intraepithelial CD8⁺ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

CD4⁺ T Cells Are Able to Promote Tumor Growth through Inhibition of Tumor-Specific CD8⁺ T-Cell Responses in Tumor-Bearing Hosts

Expression of a Natural Tumor Antigen by Thymic Epithelial Cells Impairs the Tumor-Protective CD4+ T-Cell Repertoire

Stable suppression of mutant KRAS in C26 murine colon carcinoma cells by RNA interference leads to complete loss of metastatic potential and to increased tumor immunity.

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only